Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibudilast - MediciNova

Drug Profile

Ibudilast - MediciNova

Alternative Names: AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; Pinatos

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Banyu; Columbia University; Kyorin Pharmaceutical; MediciNova; National Institute of Drug Abuse; National Institute of Neurological Disorders and Stroke; Senju Pharmaceutical; University Health Network; University of California at Los Angeles; University of Colorado at Boulder; University of New South Wales; University of Sydney
  • Class 2 ring heterocyclic compounds; Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antihyperglycaemics; Antineoplastics; Antiplatelets; Drug withdrawal therapies; Eye disorder therapies; Neuroprotectants; Non-opioid analgesics; Nootropics; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Astrocyte inhibitors; Cytokine modulators; Glial cell modulators; Leukotriene receptor antagonists; Macrophage migration inhibitory factor inhibitors; Nitric oxide synthase inhibitors; Phosphodiesterase 10A inhibitors; Phosphodiesterase 11A inhibitors; Toll-like receptor 4 antagonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Amyotrophic lateral sclerosis; Globoid cell leukodystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alcoholism; Neurological disorders; Opioid-related disorders; Substance-related disorders

Highest Development Phases

  • Marketed Allergic conjunctivitis; Asthma; Cerebrovascular disorders
  • Phase III Spinal cord disorders
  • Phase II/III Amyotrophic lateral sclerosis; Post acute COVID 19 syndrome
  • Phase II Alcoholism; Multiple sclerosis; Opioid-related disorders; SARS-CoV-2 acute respiratory disease; Substance-related disorders
  • Phase I/II Chemotherapy-induced damage; Glioblastoma
  • Phase I Adult respiratory distress syndrome; Cytokine release syndrome; Sepsis
  • Preclinical Acute lung injury; Uveal melanoma
  • Suspended Neuropathic pain
  • No development reported Brain injuries; Globoid cell leukodystrophy; Headache
  • Discontinued Diabetic neuropathies; Diabetic retinopathy

Most Recent Events

  • 12 Mar 2024 Pharmacodynamics data from a preclinical study in Acute lung injury released by MediciNova
  • 17 Jan 2024 MediciNova receives notice of grant for Ibudilast for the treatment of macular injury associated with progressive Multiple sclerosis in China
  • 06 Dec 2023 MediciNova receives a Notice of Decision to grant for patent covering ibudilast for Progressive multiple sclerosis in Europe
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top